{
    "2018-01-04": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Large-Cap Pharma Stocks to Watch Out for This New Year",
                "features": {
                    "keywords": [
                        "Large-Cap",
                        "Pharma",
                        "Stocks",
                        "Watch",
                        "New Year"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Novo Nordisk’s Xultophy, Ryzodeg, and Fiasp Could Boost Revenue Growth in 2018",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Xultophy",
                        "Ryzodeg",
                        "Fiasp",
                        "Revenue Growth",
                        "2018"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "How Is Novo Nordisk’s New Generation Insulin Segment Positioned after 3Q17?",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "New Generation",
                        "Insulin",
                        "Segment",
                        "Positioned",
                        "3Q17"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "How Novo Nordisk Performed in 3Q17",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Performed",
                        "3Q17"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}